Considering CSF NfL as a promising biomarker in neurodegenerative diseases, we hypothesize that its concentration and dynamic analysis may possibly predict cognitive progression and detect related pathological changes in de novo PD patients. This evidence concerns the gene NEFL and Parkinson disease.